This site is intended for Healthcare professionals only.

EU regulator accepts Sanofi/Regeneron Dupixent product for review

EU regulator accepts Sanofi/Regeneron Dupixent product for review

The European Medicines Agency (EMA), the European Union’s health regulator, has accepted for review the Dupixent product being developed by drug makers Sanofi and Regeneron, the companies said.

Dupixent is aimed at adults with eczema or moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy.

A biologics license application (BLA) for Dupixent was accepted for Priority Review by the U.S. Food and Drug Administration (FDA) in September 2016.

As per the U.S. Prescription Drug User Fee Act (PDUFA), the target FDA action date is March 29, 2017. The EMA and FDA have conditionally accepted Dupixent as the trade name for dupilumab.
Source: Reuters
0 comment(s) on EU regulator accepts Sanofi/Regeneron Dupixent product for review

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted

    MORE FROM BUSINESS MEDICAL DIALOGUES